Stockreport

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects [Yahoo! Finance]

Aligos Therapeutics, Inc. - Common stock  (ALGS) 
PDF Aligos anticipates dosing the first subject in Q2 2024 with topline safety and efficacy data expected in Q4 2024 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NE [Read more]